Project Details
Description
VX14-661-107: to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and With a Second CFTR Mutation That is Not Likely to Respond t
| Status | Finished |
|---|---|
| Effective start/end date | 3/1/15 → 7/1/17 |
Funding
- VERTEX PHARMACEUTICALS INCORPORATED
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.